- Home
- HRL vs EXEL Comparison
HRL vs EXEL Comparison
Compare HRL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRL
- EXEL
- Stock Information
- Founded
- HRL 1891
- EXEL 1994
- Country
- HRL United States
- EXEL United States
- Employees
- HRL N/A
- EXEL N/A
- Industry
- HRL Meat/Poultry/Fish
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HRL Consumer Staples
- EXEL Health Care
- Exchange
- HRL Nasdaq
- EXEL Nasdaq
- Market Cap
- HRL 11.9B
- EXEL 11.1B
- IPO Year
- HRL N/A
- EXEL 2000
- Fundamental
- Price
- HRL $22.40
- EXEL $42.37
- Analyst Decision
- HRL Buy
- EXEL Buy
- Analyst Count
- HRL 6
- EXEL 24
- Target Price
- HRL $29.17
- EXEL $44.73
- AVG Volume (30 Days)
- HRL 5.0M
- EXEL 3.3M
- Earning Date
- HRL 12-04-2025
- EXEL 11-04-2025
- Dividend Yield
- HRL 5.12%
- EXEL N/A
- EPS Growth
- HRL N/A
- EXEL 53.55
- EPS
- HRL 1.37
- EXEL 2.38
- Revenue
- HRL $12,058,590,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- HRL $3.00
- EXEL $9.14
- Revenue Next Year
- HRL $2.28
- EXEL $12.51
- P/E Ratio
- HRL $16.54
- EXEL $17.82
- Revenue Growth
- HRL 0.65
- EXEL 9.93
- 52 Week Low
- HRL $21.03
- EXEL $31.90
- 52 Week High
- HRL $33.80
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- HRL 43.53
- EXEL 61.04
- Support Level
- HRL $22.21
- EXEL $39.83
- Resistance Level
- HRL $21.64
- EXEL $43.72
- Average True Range (ATR)
- HRL 0.53
- EXEL 1.44
- MACD
- HRL 0.15
- EXEL 0.42
- Stochastic Oscillator
- HRL 49.56
- EXEL 82.51
About HRL Hormel Foods Corporation
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (62% of fiscal 2024 sales), US foodservice (32%), and international (6%). By product, 72% of fiscal 2024 sales were from perishable food and 28% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.